AstraZeneca Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 1990
Net Income	5,955	3,288	112	3,196	1,335	Upgrade
Depreciation & Amortization	4,934	5,480	6,530	3,149	3,762	Upgrade
Share-Based Compensation	579	619	615	277	259	Upgrade
Other Operating Activities	-1,123	421	-1,294	-1,823	-2,387	Upgrade
Operating Cash Flow	10,345	9,808	5,963	4,799	2,969	Upgrade
Operating Cash Flow Growth	5.48%	64.48%	24.26%	61.64%	13.41%	Upgrade
Capital Expenditures	-3,778	-2,571	-2,200	-2,606	-2,460	Upgrade
Acquisitions	-1,179	-1,061	-9,433	-830	-783	Upgrade
Change in Investments	-265	-201	-289	-2,245	-225	Upgrade
Other Investing Activities	1,158	873	864	5,396	2,811	Upgrade
Investing Cash Flow	-4,064	-2,960	-11,058	-285	-657	Upgrade
Dividends Paid	-4,481	-4,364	-3,856	-3,572	-3,592	Upgrade
Common Stock Issued	33	29	29	30	3,525	Upgrade
Share Repurchases	3,709	-920	12,413	3,049	0	Upgrade
Other Financing Activities	1,590	-3,408	19,889	4,388	-1,698	Upgrade
Financing Cash Flow	-6,567	-6,823	3,649	-2,203	-1,765	Upgrade
Net Cash Flow	-346	-55	-1,508	2,323	552	Upgrade
Free Cash Flow	6,567	7,237	3,763	2,193	509	Upgrade
Free Cash Flow Growth	-9.26%	92.32%	71.59%	330.84%	-59.18%	Upgrade
Free Cash Flow Margin	14.33%	16.32%	10.06%	8.24%	2.09%	Upgrade
Free Cash Flow Per Share	4.20	4.64	2.64	1.67	0.39	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.